Sponsors (3)
The bill speeds availability and reduces costs of generics and biosimilars by discouraging abusive delay petitions and clarifying FDA authority, but it does so at the cost of tighter deadlines and procedural hurdles that can limit judicial review, risk chilling legitimate safety petitions, and add administrative burdens to the FDA.
Patients with chronic conditions and other drug consumers will get faster access to lower-cost generic and biosimilar medicines because the bill discourages frivolous delay petitions and speeds market entry for competitors.
Hospitals, health systems, and the public will benefit from clearer FDA authority and greater transparency because the agency can issue guidance describing factors that identify abusive petitions, making petition handling more consistent.
Patients with chronic conditions, small businesses, and other petitioners may lose timely access to the courts because the bill requires administrative exhaustion and imposes a 180-day deadline that can bar late challengers.
Patients and public-health advocates may be deterred from filing legitimate safety or efficacy petitions because labeling or targeting of 'delay' petitions could chill citizen petitions raising real concerns.
Patients and hospitals could face reduced judicial scrutiny of some approvals if pre-approval suits are dismissed while the FDA completes administrative review, delaying or limiting independent oversight.
Based on analysis of 2 sections of legislative text.
Requires petitioners to exhaust an FDA administrative petition (with a 180‑day timeliness rule) before suing to block or delay approval of generics or biosimilars, and lets FDA publish delay‑factor guidance.
Introduced October 16, 2025 by Jeanne Shaheen · Last progress October 16, 2025
Changes the rules for citizen petitions that try to block or delay approval of generic drugs and biosimilars. It makes people or companies file an administrative petition with FDA and meet a 180‑day timeliness rule before suing, narrows the agency’s discretion about treating petitions as submitted to delay approval, and lets FDA publish the factors and guidance used to identify petitions submitted primarily to delay approval.